Faster access than browser!Similarities between Attention deficit hyperactivity disorder and Novartis
Attention deficit hyperactivity disorder and Novartis have 14 things in common (in Unionpedia): Antipsychotic, Asthma, Attention deficit hyperactivity disorder, Bipolar disorder, Epilepsy, Food and Drug Administration, Major depressive disorder, Mental disorder, Methylphenidate, Migraine, National Institute for Health and Care Excellence, Obsessive–compulsive disorder, Paracetamol, Psychiatry.
Antipsychotic
Antipsychotics, also known as neuroleptics or major tranquilizers, are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder.
Antipsychotic and Attention deficit hyperactivity disorder · Antipsychotic and Novartis ·
Asthma
Asthma is a common long-term inflammatory disease of the airways of the lungs.
Asthma and Attention deficit hyperactivity disorder · Asthma and Novartis ·
Attention deficit hyperactivity disorder
Attention-deficit hyperactivity disorder (ADHD) is a mental disorder of the neurodevelopmental type.
Attention deficit hyperactivity disorder and Attention deficit hyperactivity disorder · Attention deficit hyperactivity disorder and Novartis ·
Bipolar disorder
Bipolar disorder, previously known as manic depression, is a mental disorder that causes periods of depression and periods of abnormally elevated mood.
Attention deficit hyperactivity disorder and Bipolar disorder · Bipolar disorder and Novartis ·
Epilepsy
Epilepsy is a group of neurological disorders characterized by epileptic seizures.
Attention deficit hyperactivity disorder and Epilepsy · Epilepsy and Novartis ·
Food and Drug Administration
The Food and Drug Administration (FDA or USFDA) is a federal agency of the United States Department of Health and Human Services, one of the United States federal executive departments.
Attention deficit hyperactivity disorder and Food and Drug Administration · Food and Drug Administration and Novartis ·
Major depressive disorder
Major depressive disorder (MDD), also known simply as depression, is a mental disorder characterized by at least two weeks of low mood that is present across most situations.
Attention deficit hyperactivity disorder and Major depressive disorder · Major depressive disorder and Novartis ·
Mental disorder
A mental disorder, also called a mental illness or psychiatric disorder, is a behavioral or mental pattern that causes significant distress or impairment of personal functioning.
Attention deficit hyperactivity disorder and Mental disorder · Mental disorder and Novartis ·
Methylphenidate
Methylphenidate, sold under various trade names, Ritalin being one of the most commonly known, is a central nervous system (CNS) stimulant of the phenethylamine and piperidine classes that is used in the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy.
Attention deficit hyperactivity disorder and Methylphenidate · Methylphenidate and Novartis ·
Migraine
A migraine is a primary headache disorder characterized by recurrent headaches that are moderate to severe.
Attention deficit hyperactivity disorder and Migraine · Migraine and Novartis ·
National Institute for Health and Care Excellence
The National Institute for Health and Care Excellence (NICE) is an executive non-departmental public body of the Department of Health in the United Kingdom, which publishes guidelines in four areas.
Attention deficit hyperactivity disorder and National Institute for Health and Care Excellence · National Institute for Health and Care Excellence and Novartis ·
Obsessive–compulsive disorder
Obsessive–compulsive disorder (OCD) is a mental disorder where people feel the need to check things repeatedly, perform certain routines repeatedly (called "rituals"), or have certain thoughts repeatedly (called "obsessions").
Attention deficit hyperactivity disorder and Obsessive–compulsive disorder · Novartis and Obsessive–compulsive disorder ·
Paracetamol
--> Acetanilide was the first aniline derivative serendipitously found to possess analgesic as well as antipyretic properties, and was quickly introduced into medical practice under the name of Antifebrin by A. Cahn and P. Hepp in 1886. But its unacceptable toxic effects, the most alarming being cyanosis due to methemoglobinemia, prompted the search for less toxic aniline derivatives. Harmon Northrop Morse had already synthesised paracetamol at Johns Hopkins University via the reduction of ''p''-nitrophenol with tin in glacial acetic acid in 1877, but it was not until 1887 that clinical pharmacologist Joseph von Mering tried paracetamol on humans. In 1893, von Mering published a paper reporting on the clinical results of paracetamol with phenacetin, another aniline derivative. Von Mering claimed that, unlike phenacetin, paracetamol had a slight tendency to produce methemoglobinemia. Paracetamol was then quickly discarded in favor of phenacetin. The sales of phenacetin established Bayer as a leading pharmaceutical company. Overshadowed in part by aspirin, introduced into medicine by Heinrich Dreser in 1899, phenacetin was popular for many decades, particularly in widely advertised over-the-counter "headache mixtures", usually containing phenacetin, an aminopyrine derivative of aspirin, caffeine, and sometimes a barbiturate. Paracetamol is the active metabolite of phenacetin and acetanilide, both once popular as analgesics and antipyretics in their own right. However, unlike phenacetin, acetanilide and their combinations, paracetamol is not considered carcinogenic at therapeutic doses. Von Mering's claims remained essentially unchallenged for half a century, until two teams of researchers from the United States analyzed the metabolism of acetanilide and paracetamol. In 1947 David Lester and Leon Greenberg found strong evidence that paracetamol was a major metabolite of acetanilide in human blood, and in a subsequent study they reported that large doses of paracetamol given to albino rats did not cause methemoglobinemia. In three papers published in the September 1948 issue of the Journal of Pharmacology and Experimental Therapeutics, Bernard Brodie, Julius Axelrod and Frederick Flinn confirmed using more specific methods that paracetamol was the major metabolite of acetanilide in human blood, and established that it was just as efficacious an analgesic as its precursor. They also suggested that methemoglobinemia is produced in humans mainly by another metabolite, phenylhydroxylamine. A follow-up paper by Brodie and Axelrod in 1949 established that phenacetin was also metabolised to paracetamol. This led to a "rediscovery" of paracetamol. It has been suggested that contamination of paracetamol with 4-aminophenol, the substance von Mering synthesised it from, may be the cause for his spurious findings. Paracetamol was first marketed in the United States in 1950 under the name Triagesic, a combination of paracetamol, aspirin, and caffeine. Reports in 1951 of three users stricken with the blood disease agranulocytosis led to its removal from the marketplace, and it took several years until it became clear that the disease was unconnected. Paracetamol was marketed in 1953 by Sterling-Winthrop Co. as Panadol, available only by prescription, and promoted as preferable to aspirin since it was safe for children and people with ulcers. In 1955, paracetamol was marketed as Children's Tylenol Elixir by McNeil Laboratories. In 1956, 500 mg tablets of paracetamol went on sale in the United Kingdom under the trade name Panadol, produced by Frederick Stearns & Co, a subsidiary of Sterling Drug Inc. In 1963, paracetamol was added to the British Pharmacopoeia, and has gained popularity since then as an analgesic agent with few side-effects and little interaction with other pharmaceutical agents. Concerns about paracetamol's safety delayed its widespread acceptance until the 1970s, but in the 1980s paracetamol sales exceeded those of aspirin in many countries, including the United Kingdom. This was accompanied by the commercial demise of phenacetin, blamed as the cause of analgesic nephropathy and hematological toxicity. In 1988 Sterling Winthrop was acquired by Eastman Kodak which sold the over the counter drug rights to SmithKline Beecham in 1994. Available without a prescription since 1959, it has since become a common household drug. Patents on paracetamol have long expired, and generic versions of the drug are widely available.
Attention deficit hyperactivity disorder and Paracetamol · Novartis and Paracetamol ·
Psychiatry
Psychiatry is the medical specialty devoted to the diagnosis, prevention and treatment of mental disorders.
Attention deficit hyperactivity disorder and Psychiatry · Novartis and Psychiatry ·
The list above answers the following questions
- What Attention deficit hyperactivity disorder and Novartis have in common
- What are the similarities between Attention deficit hyperactivity disorder and Novartis
Attention deficit hyperactivity disorder and Novartis Comparison
Attention deficit hyperactivity disorder has 205 relations, while Novartis has 316. As they have in common 14, the Jaccard index is 2.69% = 14 / (205 + 316).
References
This article shows the relationship between Attention deficit hyperactivity disorder and Novartis. To access each article from which the information was extracted, please visit:
